Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893781 | 0.93 | MDM2 (0.60) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL9893677 | 0.92 | MDM2 (0.70) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL1437280 | 0.91 | MDM2 (0.48) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL9894203 | 0.90 | MDM2 (0.73) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL1437158 | 0.90 | MDM2 (0.47) | MDM2 | |
| SCHEMBL1437360 | 0.83 | MDM2 (0.56) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL9894027 | 0.83 | MDM2 (0.58) | MDM2ALDH1A1 | |
| SCHEMBL9893616 | 0.83 | MAPT (0.49) | MDM2TP53POLB | |
| SCHEMBL1437181 | 0.83 | MDM2 (0.55) | MDM2ALDH1A1HPGDMAPK1TDP1 | |
| SCHEMBL1438216 | 0.82 | MDM2 (0.49) | MDM2ALDH1A1HPGDMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885ALDH1A1 4361/4885HPGD 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.